AMRN Reply Brief - Does it change our view?
AMRN filed its reply brief (attached below) in the Vascepa Appeal, and now all the briefs are in for the appeal. We analyzed the Reply brief and review the patents and case to put the Reply brief into context. We explain our initial and current position with respect to AMRN's chances in this appeal to overturn the District Court's ruling that their patents are obvious, and therefore invalid.
Disclaimer:
*Emanuel "Manny" Vacchiano, J.D., PhD., is a licensed U.S. patent attorney.
No attorney-client relationship is established by your purchase of this product. If you would like to inquire about a possible legal representation by Dr. Vacchiano and his law firm, Double Helix Law, LLC, please contact Dr. Vacchiano at mannyv@doublehelixlaw.com.
You are reminded as indicated in our terms, that in exchange for getting this analysis at a very reasonable price you agree not to share it with others.
Information provided on ampbiotechresearch.com and by Manny Vacchiano, Amp Biotech Research, LLC, or any of its consultants on the Amp web site and in any of our reports, products and services are for information only and are not investment or legal advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.
#AMRN #Vascepa #triglycerides #cardiovascular #ANDA #patents
Hardestyba, Thanks for the comments. We have made progress on looking at AMRN's patent office activity. We plan to get that posted up later this month. Our immediate attention will be on tomorrow's hearing. We plan to post tomorrow about this. Manny